Breakthrough in Biocatalysis: Advancing Oral PCSK9 Inhibitors

Merck scientists have published a landmark paper in Science describing a novel biocatalytic method for the large-scale synthesis of enlicitide decanoate, an investigational oral PCSK9 inhibitors. The approach employs a tailored suite of enzymes to assemble this complex macrocyclic peptide through selective fragment formation, coupling, and macrocyclization, followed by crystallization-based purification. This process enables production that traditional synthetic methods cannot achieve and provides a sustainable blueprint for manufacturing such therapeutics at scale.

Enzymatic Efficiency for Cardiovascular Access

The publication highlights how biocatalysis delivers both manufacturing efficiencies and environmental advantages that support broader patient access to innovative cardiovascular therapies. By replacing conventional chemical catalysts with enzymes, the method reduces resource intensity while maintaining the structural integrity required for enlicitide’s oral bioavailability. These efficiencies are particularly relevant for macrocyclic peptides, which combine the potency and selectivity of biologic therapies with the convenience of daily oral dosing, potentially expanding treatment options for patients who face barriers with injectable monoclonal antibody PCSK9 inhibitors.

Engineering Enzymes for Scalable Peptide Production

Merck’s strategy builds on more than 25 years of investment in biocatalysis, applying enzymes specifically engineered for peptide bond formation and ring closure. The process integrates enzymatic steps with crystallization purifications to achieve high purity and yield at commercial scale. This methodology directly addresses the challenges of synthesizing intricate ring-shaped molecules capable of disrupting protein-protein interactions while preserving oral bioavailability, thereby establishing a replicable framework for future macrocyclic peptide candidates.

Implications for Value-Based Cardiovascular Care

The development of an oral PCSK9 inhibitors through this scalable, sustainable route carries meaningful implications for health economics and outcomes research, market access, and reimbursement strategies. An effective oral formulation could reduce administration-related costs and improve adherence compared with injectable therapies, potentially lowering overall expenditures in atherosclerotic cardiovascular disease management. Manufacturing efficiencies and environmental benefits may further support favorable pricing and reimbursement negotiations by demonstrating reduced production burdens and alignment with value-based access initiatives aimed at addressing the global cardiovascular epidemic.